Home › Funds › Commodore Capital LP › SYRE

Commodore Capital LP position in SYRE

SPYRE THERAPEUTICS INC · Health Care

Commodore Capital LP reported holding 846,786 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$75.2M, representing 4.48% of its reported portfolio and ranking #7 among its reported holdings. Commodore Capital LP has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)846.79K sh
Reported value held$75.18M
Portfolio Weight4.48%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Commodore Capital LP's SYRE position evolved

Commodore Capital LP first disclosed a stake in SYRE in Q3 2023 at 116,324 shares (US$1.4M). The position peaked in Q1 2026 at 1,912,380 shares, worth US$96.5M. Across 12 filings, Commodore Capital LP increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 846,786 shares valued at US$75.2M — a reduction of -1,065,594 shares quarter over quarter.. Notable position changes include a 1520% increase in Q4 2023 (shares rose 9% over the following quarter), a 56% trim in Q2 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 116.32K $1.42M New
Q4 2023 1.88M $40.55M Add
Q1 2024 1.88M $71.46M Hold
Q2 2024 1.99M $46.74M Add
Q3 2024 1.99M $58.47M Hold
Q4 2024 1.99M $46.28M Hold
Q1 2025 1.99M $32.08M Hold
Q2 2025 1.99M $29.76M Hold
Q3 2025 1.99M $33.32M Hold
Q4 2025 2.39M $78.24M Add
Q1 2026 1.91M $96.46M Reduce
Q2 2026 846.79K $75.18M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has Commodore Capital LP held SYRE?

Commodore Capital LP has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Commodore Capital LP's current position in SYRE?

As of Q2 2026, Commodore Capital LP holds 846.79K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $75.18M, representing 4.48% of its reported portfolio and ranking #7.

Has Commodore Capital LP been buying or selling SYRE?

In the latest 13F filing (Q2 2026), Commodore Capital LP reduced its position in SYRE. The position peaked in Q1 2026 at 1.91M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.